Innovent Biologics (HKSE:01801) Inventories, Work In Process: HK$362 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:01801 Innovent Biologics Inc HKSE:01801
84 GF Score
Price HK$88.95
GF Value HK$100.93
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Innovent Biologics Inventories, Work In Process?

Innovent Biologics HKSE:01801 -5.57% 84 Inventories, Work In Process is HK$362 Mil as of Dec. 2025. GuruFocus rates HKSE:01801 with a GF Score™ of 84/100 and a GF Value™ of HK$100.93 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Work in process is the part of a manufacturer's inventory that is in the production process and has not yet been completed and transferred to the finished goods inventory. Innovent Biologics's work in process for the quarter that ended in Dec. 2025 was HK$362 Mil.

Innovent Biologics Inventories, Work In Process Historical Data

* Premium members only.

The historical data trend for Innovent Biologics's Inventories, Work In Process can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Innovent Biologics Inventories, Work In Process Chart

Innovent Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Work In Process
Get a 7-Day Free Trial Premium Member Only Premium Member Only 468.64 541.17 355.59 205.15 361.57

Innovent Biologics Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Inventories, Work In Process Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 355.59 0.00 205.15 0.00 361.57
HKSE:01801
84GF Score
Innovent Biologics Inc HKSE:01801
Inventories, Work In Process is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Innovent Biologics Inventories, Work In Process Calculation

That part of a manufacturer's inventory that is in the production process and has not yet been completed and transferred to the finished goods inventory. This account contains the cost of the direct material, direct labor, and factory overhead placed into the products on the factory floor. A manufacturer must disclose in its financial statements the cost of its work-in-process as well as the cost of finished goods and materials on hand.

What does a Inventories, Work In Process of HK$362 Mil mean?
Innovent Biologics (HKSE:01801) has a Inventories, Work In Process of HK$362 Mil as of Dec. 2025. Work in progress is the portion of inventory containing goods that are unfinished. View historical data on Innovent Biologics and its competitors.
Is Innovent Biologics' Inventories, Work In Process too high?
Innovent Biologics' current Inventories, Work In Process is HK$362 Mil. Overall, Innovent Biologics has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Innovent Biologics' Inventories, Work In Process compare to VRTX and REGN?
Innovent Biologics' Inventories, Work In Process of HK$362 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Work In Process for a Biotechnology company?
A good Inventories, Work In Process depends on the Biotechnology industry context. However, Inventories, Work In Process should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Work In Process mean?
A high Inventories, Work In Process can signal that a stock is expensive relative to its fundamentals. Work in progress is the portion of inventory containing goods that are unfinished. View historical data on Innovent Biologics and its competitors. Innovent Biologics's current Inventories, Work In Process is HK$362 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innovent Biologics stock overvalued right now?
Based on GuruFocus' analysis, Innovent Biologics (HKSE:01801) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$100.93, compared to a current price of HK$88.95 — trading 11.9% below its estimated fair value. The current Inventories, Work In Process is HK$362 Mil. Innovent Biologics' overall GF Score™ is 84/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Work In Process calculated?
Inventories, Work In Process is calculated from a company's financial statements. For Innovent Biologics (HKSE:01801), the current Inventories, Work In Process is HK$362 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Innovent Biologics (HKSE:01801) Overvalued in 2026?

Based on GuruFocus' analysis, Innovent Biologics stock appears to be undervalued. The current stock price of HK$88.95 is trading 11.9% below its estimated GF Value™ of HK$100.93. GuruFocus considers Innovent Biologics to be Modestly Undervalued.

Key valuation signals for HKSE:01801:

  • Inventories, Work In Process: HK$362 Mil
  • GF Value™: HK$100.93 vs. price of HK$88.95 (11.9% below fair value)
  • GF Score™: 84/100 with 2 warning signs

No single metric tells the full story. See the HKSE:01801 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Innovent Biologics Business Description

Address 168 Dongping Street, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN, 215123
Innovent Biologics is one of the leading biotechnology companies in China. Listed on the Hong Kong stock exchange in 2018, Innovent has 12 commercialized oncology products and four commercialized nononcology products as of January 2026, and 34 drugs in its research and development pipeline. Its core assets are Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists (NRDL) for the first-line treatment of five major cancers, and mazdutide, a GLP-1/glucagon dual agonist drug for weight loss, fat breakdown, and Type 2 diabetes. Mazdutide is the first domestic GLP-1 drug produced and competes with Eli Lilly and Novo Nordisk in China. Tyvyt's main competition includes drugs from Junshi, Jiangsu Hengrui, BeOne, Merck, and Bristol Myers.
84GF Score

Get the complete analysis for HKSE:01801

Inventories, Work In Process is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$88.95
Price
HK$100.93
GF Value